- Home
- URGN
URGN
UroGen Pharma Ltd.
as 05-30-2025 4:00pm EST
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | RA'ANANA |
| Market Cap: | 463.2M | IPO Year: | 2017 |
| Target Price: | $27.92 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.42 - $20.70 | Next Earning Date: | 05-12-2025 |
| Revenue: | $91,871,000 | Revenue Growth: | 8.98% |
| Revenue Growth (this year): | 35.06% | Revenue Growth (next year): | 112.94% |
Latest UroGen Pharma Ltd. News
URGN Breaking Stock News: Dive into URGN Ticker-Specific Updates for Smart Investing
GOBankingRates
11 hours ago
7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs
GOBankingRates
11 hours ago
3 International Vacations That Are Cheaper Than an iPhone
GOBankingRates
11 hours ago
Suze Orman’s 5 Best Tips for Saving Money Even When Living Paycheck to Paycheck
Yahoo Finance
11 hours ago
This week in Trumponomics: Too bad TACO isn’t true
The Guardian
11 hours ago
Starmer says Farage would spook the City and give us Truss 2 – he could be right
Yahoo Finance Video
11 hours ago
AI ecosystem isn't just Nvidia: Unlock it further with this ETF
Benzinga
11 hours ago
Is Dave Ramsey's Home Buying Advice Realistic For The Average Homeowner?
Reuters
11 hours ago
Ford recalls more than 29,000 vehicles in the US, NHTSA says
Compare URGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "URGN UroGen Pharma Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.